- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02308306
Predictive Markers of the Effects of Opioid Therapy (ABILITY)
Predictive Markers of the Effects of Opioid Therapy in Opioid naïve Patients With Chronic Pain: an International, Multi-centre, Observational Cohort Study (ABILITY)
The overall goal of the ABILITY study is to help improve pain diagnostics and treatment by developing an implementable clinical computerised decision support system based on individual patient characteristics.
The investigators hypothesize that successful pain control with opioids can be predicted before treatment initiation with advanced data analyses of data originating from pre-treatment EEG, QST and pain-related catastrophic thinking.
The primary objective of this study is the identification of markers that can be used to individualize treatment recommendations, i.e. to reliably predict the response of pain to opioids.
Markers are selected among the most promising data and machine-learning methods are used for the prediction. This includes determining the associations between a battery of selected pre-treatment clinical predictive markers and the analgesic effect of opioid treatment in opioid naïve chronic pain patients, including indication and responder identification.
The key secondary objectives are as follows: to investigate pre-treatment clinical predictive markers as predictors of opioid treatment efficacy and effectiveness in terms of the following:
- Pain intensity and unpleasantness
- Use of rescue analgesics
- Physical functioning
- Global improvement and satisfaction with treatment
Przegląd badań
Status
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Pellenberg
-
Leuven, Pellenberg, Belgia, 3212
- KU Leuven and the Leuven Centre for Algology & Pain Management
-
-
-
-
-
Aarhus C, Dania, 8000
- Department of Rheumatology, Aarhus University Hospital
-
Give, Dania, 7323
- Friklinikken
-
Ringsted, Dania, 4100
- Hospitalet Valdemar
-
-
-
-
-
Ljubljana, Słowenia, 1000
- Ljubljana University Medical Centre, Department of Anaesthetics and Surgical Intensive Care
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Pain duration ≥ 3 months.
- Minimum baseline pain intensity ≥ 4 on a 0-10 numerical rating scale (over the past week).
- Maximum baseline pain intensity < 9 on a 0-10 numerical rating scale (over the past week).
- Prescribed opioid treatment (ATC: N02)
- Anticipated to stay on prescribed opioid treatment throughout the study, i.e. >14 days.
- Anticipated to stay on any concomitant non-opioid treatment throughout the study, i.e. >14 days.
- Subject may be male or female, age >18 years old.
- Is willing and able to comply with study procedures as judged by the site investigator.
- Subject has voluntarily signed and dated the study-specific informed consent form, approved by an Independent Ethics Committee, after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent form must be signed before any study-specific procedures are performed.
Exclusion Criteria:
- Has a mental incapacity or language barriers precluding adequate understanding of study procedures.
- Is considered by the site investigator unsuitable to participate in the study for any other reason, for instance due to a significant serious underlying condition.
- Recently received opioids on a daily basis (within the last 10 weeks).
- Current alcohol or substance abuse, according to the site investigator's medical judgement.
- Is anticipated to undergo a painful procedure(s) (e.g. surgery) during the study, which can interfere with the experience of the chronic pain condition for which the subject is to receive opioids.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: Kohorta
- Perspektywy czasowe: Spodziewany
Kohorty i interwencje
Grupa / Kohorta |
---|
Opioid analgesics
Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Reduction of chronic pain assessed by 0-10 numerical rating scale (NRS) scores
Ramy czasowe: After 14-days of opioid treatment
|
The absolute and percentage change from baseline in ratings of average pain in the past week at Day 14.
Of note, a percentage change of ≥30% is considered clinically significant.
|
After 14-days of opioid treatment
|
Improvement of health-related quality of life assessed by QLQ-C30 scores
Ramy czasowe: After 14 days of opioid treatment
|
The absolute and percentage change from baseline in ratings of health-related quality of life in the past week at Day 14.
A subjectively significant change in QLQ-C30 scores is one that is ≥10 from baseline.
|
After 14 days of opioid treatment
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
BPI worst pain in the past week
Ramy czasowe: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI least pain in the past week
Ramy czasowe: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI current pain in the past week
Ramy czasowe: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI pain severity in the past week
Ramy czasowe: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI pain interference score
Ramy czasowe: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
Improvement score
Ramy czasowe: Day 14 post-treatment
|
Proportion with score >4
|
Day 14 post-treatment
|
Concomitant and rescue medication
Ramy czasowe: Until 14 days post-treatment
|
Until 14 days post-treatment
|
|
Adverse events
Ramy czasowe: Until 14 days post-treatment
|
Number (%) of the following:
|
Until 14 days post-treatment
|
Współpracownicy i badacze
Sponsor
Śledczy
- Krzesło do nauki: Asbjørn M Drewes, MD, PhD, DMSci, Aalborg University Hospital, Denmark
- Dyrektor Studium: Anne E Olesen, MSc (Pharm), PhD, Aalborg University Hospital, Denmark
- Dyrektor Studium: Kasper Grosen, MHSc, PhD, Aarhus University / Aarhus University Hospital, Denmark
- Główny śledczy: Mogens Pfeiffer-Jensen, MD, PhD, Aarhus University Hospital, Denmark
- Główny śledczy: Michael Kamp-Jensen, MD, PhD, Hospitalet Valdemar, Denmark
- Główny śledczy: Bart Morlion, MD, PhD, University of Leuven / University Hospitals Leuven, Belgium
- Główny śledczy: Gorazd Pozlep, MD, Ljubljana University Medical Centre, Slovenia
- Główny śledczy: Torsten Jonsson, MD, Hospitalet Valdemar, Denmark
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- ABILITY
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .